LeMaitre Vascular, Inc. (LMAT): Price and Financial Metrics
GET POWR RATINGS... FREE!
LMAT POWR Grades
- LMAT scores best on the Growth dimension, with a Growth rank ahead of 83.65% of US stocks.
- The strongest trend for LMAT is in Quality, which has been heading up over the past 31 weeks.
- LMAT's current lowest rank is in the Momentum metric (where it is better than 49.3% of US stocks).
LMAT Stock Summary
- LMAT's current price/earnings ratio is 47.02, which is higher than 79.01% of US stocks with positive earnings.
- Price to trailing twelve month operating cash flow for LMAT is currently 28.41, higher than 81.68% of US stocks with positive operating cash flow.
- With a year-over-year growth in debt of 207.71%, Lemaitre Vascular Inc's debt growth rate surpasses 95.2% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Lemaitre Vascular Inc, a group of peers worth examining would be THRM, LNN, BHE, SCL, and ITI.
- Visit LMAT's SEC page to see the company's official filings. To visit the company's web site, go to www.lemaitre.com.
LMAT Valuation Summary
- LMAT's price/earnings ratio is 47.1; this is 38.53% higher than that of the median Healthcare stock.
- LMAT's price/earnings ratio has moved up 261.1 over the prior 180 months.
- LMAT's price/earnings ratio has moved up 261.1 over the prior 180 months.
Below are key valuation metrics over time for LMAT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LMAT | 2021-05-25 | 7.6 | 5.8 | 42.9 | 32.4 |
| LMAT | 2020-04-29 | 5.3 | 4.2 | 34.6 | 28.8 |
| LMAT | 2019-09-19 | 6.4 | 5.2 | 38.4 | 31.1 |
| LMAT | 2015-09-02 | 3.1 | 3.3 | 38.6 | 21.7 |
| LMAT | 2015-05-11 | 2.5 | 2.7 | 33.4 | 18.6 |
| LMAT | 2008-02-06 | 2.2 | 1.7 | -35.0 | -27.4 |
LMAT Growth Metrics
- Its year over year revenue growth rate is now at 12.9%.
- Its 2 year net income to common stockholders growth rate is now at -1.21%.
- The 3 year net cashflow from operations growth rate now stands at 16.85%.
The table below shows LMAT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-03-31 | 134.698 | 39.685 | 23.975 |
| 2020-12-31 | 129.366 | 34.8 | 21.22 |
| 2020-09-30 | 121.988 | 26.242 | 18.8 |
| 2020-06-30 | 114.672 | 16.6 | 16.471 |
| 2020-03-31 | 119.304 | 15.587 | 17.595 |
| 2019-12-31 | 117.232 | 14.179 | 17.934 |
LMAT Price Target
For more insight on analysts targets of LMAT, see our LMAT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $62.00 | Average Broker Recommendation | 1.58 (Moderate Buy) |
LMAT Stock Price Chart Interactive Chart >
LMAT Price/Volume Stats
| Current price | $55.01 | 52-week high | $64.50 |
| Prev. close | $54.71 | 52-week low | $27.91 |
| Day low | $54.70 | Volume | 49,822 |
| Day high | $55.53 | Avg. volume | 135,151 |
| 50-day MA | $56.19 | Dividend yield | 0.8% |
| 200-day MA | $46.85 | Market Cap | 1.13B |
LeMaitre Vascular, Inc. (LMAT) Company Bio
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease. The company was founded in 1983 and is based in Burlington, Massachusetts.
LMAT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $55.01 | $49.35 | -2% |
We started the process of determining a valid price forecast for Lemaitre Vascular Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Lemaitre Vascular Inc ranked in the 54th percentile in terms of potential gain offered. As for the metrics that stood out in our discounted cash flow analysis of Lemaitre Vascular Inc, consider:
- LMAT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 48.83% of tickers in our DCF set.
- Relative to other stocks in its sector (Healthcare), Lemaitre Vascular Inc has a reliance on debt greater than just 23.87% of them.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -3% |
| 1% | -3% |
| 2% | -2% |
| 3% | -1% |
| 4% | 0% |
| 5% | 1% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as LMAT, try AMED, LCI, PCRX, TMO, and UNH.
Latest LMAT News From Around the Web
Below are the latest news stories about Lemaitre Vascular Inc that investors may wish to consider to help them evaluate LMAT as an investment opportunity.
Is LeMaitre (LMAT) a Solid Growth Stock? 3 Reasons to Think " Yes "LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market. |
LeMaitre Will Announce Second Quarter 2021 Earnings Results on July 29, 2021BURLINGTON, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2021 financial results on Thursday, July 29, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook. |
LeMaitre Vascular (LMAT) to Report Q2 Results: Wall Street Expects Earnings GrowthLeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
LeMaitre prices 1M-share offering at $54.50LeMaitre Vascular (LMAT) has priced its public offering of 1M common shares at $54.50/share, for expected gross proceeds of ~$54.5M.Underwriters' over-allotment is an additional 150K shares. Net proceeds will be used to repay outstanding borrowings, for general corporate purposes, working capital and to fund potential future acquisitions.Closing date is July... |
LeMaitre Vascular Sees Better Than Expected Q2 Sales, Raises $55M Via Equity At 9% DiscountView more earnings on LMATSee more from BenzingaClick here for options trades from BenzingaCelldex Therapeutics Raises 0M Via Equity To Support Development Of Skin Disease CandidatescPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. |
LMAT Price Returns
| 1-mo | -11.70% |
| 3-mo | 5.08% |
| 6-mo | 14.99% |
| 1-year | 83.41% |
| 3-year | 64.67% |
| 5-year | 235.73% |
| YTD | 36.45% |
| 2020 | 14.09% |
| 2019 | 53.77% |
| 2018 | -25.13% |
| 2017 | 26.58% |
| 2016 | 48.46% |
LMAT Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching LMAT
Here are a few links from around the web to help you further your research on Lemaitre Vascular Inc's stock as an investment opportunity:Lemaitre Vascular Inc (LMAT) Stock Price | Nasdaq
Lemaitre Vascular Inc (LMAT) Stock Quote, History and News - Yahoo Finance
Lemaitre Vascular Inc (LMAT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...